BACKGROUND: Colorectal cancer is among the three most frequent neoplasms in Brazil, being a public health problem. OBJECTIVE: To describe distribution pattern of colorectal cancer mortality in Brazil and regions, according to sex, between 1996 and 2015. METHODS: Values of standardized and stratified mortality rates by sex between 1996 and 2015 were used, through polynomial regression models and joinpoint analysis. RESULTS: It was observed that, for linear trends in mortality rates, for both sexes, there is a statistically significant trend increasing in both models, with rates and trends, and higher for men than for women, respectively, 7.3% per year (R2=0.95, P<0.001) and 6.5% per year (R2=0.87, P<0.001). It is observed a difference in magnitude and behavior of trend between the regions. CONCLUSION: It is understood that it is important to know the trend of rates in order to define priority populations for early interventions that increase survival and reduce mortality.

Background: Cervical cancer is the main cause of cancer deaths in some developing countries. Age-related cervical cancer incidence has been fundamental for understanding the different stages of carcinogenesis concepts. No Brazilian study explored the environmental risk factors involved on cervical cancer, according to age groups taking 70's sexual revolution in Brazil as reference. Aim: To determine the prevalence of epidemiological and clinical aspects related to cervical cancer development in a sample of three age groups of Brazilian women based on 70's sexual revolution. Methods: A cross-section study was proceeded in a hospital-based cohort of women with altered Pap-test refereed to the National Cancer Institute for Colposcopy and treatment from October 2004 to May 2006. Two register nurses interviewed all patients ascertaining risk factors and clinical characteristics. Biopsy, partial ablation were used for CIN-1, and conization was the treatment for CIN-2/3. Results: From 318 women included in the study, 42.8% were 18 -30 years old (born after 1975), 43.4% were 31 -49 years old (born 1955-1975), and 13.8% were 50 -68 years old (born 1936-1954). Pregnancies (OR = 1.16; CI95%: 1.01 -1.34) and menarche under 12 years old (OR = 1.95; CI95%: 1.17 -3.25) were independently associated to CIN2-3/cancer in 18 -30 age group; menopause age (OR = 1.21; CI95%: 1.04 -1.41) and current smoking habit (OR = 1.37; CI95%: 1.10 -1.70) were associated to CIN2-3/cancer in 31 -49 age group; no statistical significance was observed for 50 -68 age group. Conclusion: Brazilian women present distinct risk for cervical cancer according to the generation they belong, when taking the Brazilian sexual revolution on 70's as a reference.

No abstract

No abstract

No abstract

OBJECTIVES: To analyze therapeutic strategies utilization and resources consumption in patientsaffected by Crohn Disease (CD) or Ulcerative Colitis (UC) in an Italian real-worldsetting, Veneto Region. METHODS: An observational retrospective cohort analysis of administrative databases of Veneto Region was performed. Patients with a hospitalization discharge diagnosis of MC or UC (ICD-9-CM codes: 555-556) or exemption code for CD or UC (codes:009.555e009.556) from 01/01/2011 to 30/09/2016 (inclusion period) were included. The index-date (ID) was the 1stbiologic agent prescription during the inclusion period. This study refers to patients naive to index biological agent during the inclusion period.All patients were characterized 12 months prior the ID and followed up after the ID for 9 months (Follow-up, F-up). RESULTS: We identified 18,133 patients with a diagnosis of MC or UC; mean age was 52.3 and 54.8% were males. CD and UC prevalence in the study population was estimated at 0.4% (denominator¼ 4,937,854). A total of933 were naïve to index biological agent; among them, 495 patients were treated with infliximab, 370 with adalimumab, 51 with golimumab and 17 with vedolizumab. It is important to mention that infliximab is tracked in our database starting from 2015 and vedolizumab starting from May 2016.The percentage of patients who required dose escalation, during F-up, was: 12.4% for adalimumab, 13.7% for golimumab, 7.3% for infliximab and none for vedolizumab. During the F-up, the percentage of patients who switched their ID therapy was: 5.7% for adalimumab, 15.7% for golimumab, 6.9% for infliximab and none for vedolizumab. Per patient disease cost at one year, was: V12,242 for adalimumab, V12,630 for golimumab, V10,203 for infliximab, V10,875 for vedolizumab. OBJECTIVES:To compare the clinical profile and healthcare resource utilization of women vs. men with non-alcoholic fatty liver disease (NAFLD) in a large population-based study. METHODS: We identified NAFLD patients among 2.2 million people in the computerized database of a national payer-provider health fund in Israel using natural language processing of ultrasonography and dynamic imaging reports, diagnoses, fibrosis scores (>0.67) or consecutively elevated liver enzymes. Patients with viral hepatitis or alcoholism were excluded. Among active members on January 2017, NAFLD male patients were age-matched to female patients. Standardized mean differences (SMD) > 0.1 were regarded substantial. RESULTS: A total of 91,304 women and 102,243 men with NAFLD were identified, with a median age of 61 vs. 54 years old respectively. After age matching, the prevalence of cardiovascular disease was lower in women vs. men (17% vs. 29%, SMD¼0.29) but similar for diabetes (30% vs. 33%), hypertension (51% vs. 50%), cancer (16% vs. 17%) and kidney disease (23% vs. 27%). Women exhibited higher median BMI (30.5 vs. 29.2, SMD¼0.22), HDL and LDL (107 vs. 98), lower ALT (19 vs. 23, SMD¼0.25), AST, triglycerides (127 vs. 131, SMD¼0.10) and similar HbA1c. According to ultrasound...